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Cannabinoids, the bioactive constituents of cannabis, exert a wide array of effects on the brain by engaging Type 1 cannabinoid recep-
tor (CB1R). Accruing evidence supports that cannabinoid action relies on context-dependent factors, such as the biological characteris-
tics of the target cell, suggesting that cell population-intrinsic molecular cues modulate CB1R-dependent signaling. Here, by using a
yeast two-hybrid-based high-throughput screening, we identified BiP as a potential CB1R-interacting protein. We next found that
CB1R and BiP interact specifically in vitro, and mapped the interaction site within the CB1R C-terminal (intracellular) domain and
the BiP C-terminal (substrate-binding) domain-a. BiP selectively shaped agonist-evoked CB1R signaling by blocking an “alternative”
Gq/11 protein-dependent signaling module while leaving the “classical” Gi/o protein-dependent inhibition of the cAMP pathway unaf-
fected. In situ proximity ligation assays conducted on brain samples from various genetic mouse models of conditional loss or gain of
CB1R expression allowed to map CB1R-BiP complexes selectively on terminals of GABAergic neurons. Behavioral studies using canna-
binoid-treated male BiP1/2 mice supported that CB1R-BiP complexes modulate cannabinoid-evoked anxiety, one of the most frequent
undesired effects of cannabis. Together, by identifying BiP as a CB1R-interacting protein that controls receptor function in a signaling
pathway- and neuron population-selective manner, our findings may help to understand the striking context-dependent actions of can-
nabis in the brain.
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Significance Statement
Cannabis use is increasing worldwide, so innovative studies aimed to understand its complex mechanism of neurobiological
action are warranted. Here, we found that cannabinoid CB1 receptor (CB1R), the primary molecular target of the bioactive
constituents of cannabis, interacts specifically with an intracellular protein called BiP. The interaction between CB1R and BiP
occurs selectively on terminals of GABAergic (inhibitory) neurons, and induces a remarkable shift in the CB1R-associated sig-
naling profile. Behavioral studies conducted in mice support that CB1R-BiP complexes act as fine-tuners of anxiety, one of the
most frequent undesired effects of cannabis use. Our findings open a new conceptual framework to understand the striking
context-dependent pharmacological actions of cannabis in the brain.
Introduction
Preparations of the hemp plant Cannabis sativa L. have been
used by humankind for millennia. During the last decades, there
has been a strong renaissance in the study of the molecular and
pharmacological bases of cannabinoid action; and, in concert,
many countries have approved the use of cannabinoid-based
medicines and standardized preparations of medicinal cannabis
(Hill, 2015; Abrams, 2018). Both the therapeutic and the adverse
effects of cannabis are mostly attributed to a single molecule, D9-
tetrahydrocannabinol (THC) (Mechoulam et al., 2014). This
compound engages and activates two specific G-protein-coupled
receptors (GPCRs), designated as cannabinoid CB1 receptor
(CB1R) and cannabinoid CB2 receptor (CB2R) (Pertwee et al.,
2010). CB1R is one of the most abundant GPCRs in the mamma-
lian brain (Katona and Freund, 2008; Pertwee et al., 2010; Dudok
et al., 2015). It mediates a large number of pharmacological
effects of THC, and, on binding endocannabinoids (anandamide
and 2-arachidonoylglycerol), participates in the physiological
control of multiple processes, such as motor behavior, learning
and memory, fear and anxiety, pain, food intake, and energy me-
tabolism (Piomelli, 2003; Mechoulam et al., 2014).
The precise molecular mechanism of CB1R action remains
unsolved. For example, CB1R couples to the inhibitory family of
heterotrimeric G-proteins (Gi/o), but its expression and signaling
efficacy differ remarkably between excitatory and inhibitory neu-
rons (Steindel et al., 2013), which could explain, at least in part,
the widely reported biphasic effects elicited by THC and other
CB1R agonists (Bellocchio et al., 2010; Rey et al., 2012;
Mechoulam and Parker, 2013). Likewise, under different cellular
settings, CB1R can signal through other G-protein families, such
as Gq/11 and Gs (Lauckner et al., 2005; Priestley et al., 2017).
Furthermore, CB1R activation protects neurons from death in a
wide array of pathologic conditions (Fernández-Ruiz, 2019),
while it triggers apoptosis of brain cancer cells (Velasco et al.,
2012). How these striking differences in signaling efficacy, G-
protein coupling, and biological response occur is not under-
stood. Together, these observations suggest a cell population-
selective action of CB1R colligated to the physiopathological con-
text of the target cell expressing the receptor. Understanding
how CB1R evokes such varying responses is important to clarify
the neurobiological role of the endocannabinoid system and,
potentially, to improve the design of CB1R-targeted therapies.
Interaction with regulatory proteins represents one of the piv-
otal molecular processes by which GPCR-evoked signaling is
affected. Diverse subsets of these interacting proteins assist
GPCRs during biosynthesis, trafficking, activation, desensitiza-
tion, and degradation (Maurice et al., 2011). Aside from the most
ubiquitous GPCR-associated proteins (i.e., G-proteins, b -arrest-
ins, and GPCR kinases), specific interacting partners have been
identified for particular types of receptors (e.g., NHERF proteins
for adrenergic receptors and others, and Homer proteins for
metabotropic glutamate receptors and others) (Wheeler et al.,
2007; Magalhaes et al., 2012) . Regarding CB1R, several intracellu-
lar proteins (led by CRIP1a) (Howlett et al., 2010; Guggenhuber et
al., 2016), as well as membrane-anchored GPCRs (e.g., serotonin
5-HT2A and adenosine A2A receptors) (Viñals et al., 2015; Moreno
et al., 2018), have been proposed as receptor interactors. However,
most studies on these putative protein complexes have been con-
ducted in vitro, and only subtle effects have been unraveled so far
in vivo.
Here, we hypothesized that unidentified neuron population-
specific CB1R-interacting proteins modulate cannabinoid signal-
ing in the brain. By using a yeast two-hybrid (Y2H)-based
approach, complemented with a wide array of molecular, genetic,
pharmacological, and behavioral procedures, we identified the
protein BiP as a new modulator of biased signaling of CB1R, and
defined the molecular features, signal-transduction consequen-
ces, neuroanatomical mapping, and behavioral outcomes of the
CB1R-BiP interaction.
Materials and Methods
Gene constructs. Y2H vectors were generated by PCR and subse-
quent restriction cloning by using pGBT9 and pGAD as vectors
(ClonTech, TaKaraBio). Short amino-acid stretches (CB1R mutants)
were ligated by using long annealing oligonucleotides with protruding
overhangs. The cDNA encoding full-length BiP was provided by Valerie
Petegnief (Institute for Biomedical Research of Barcelona), and expres-
sion vectors encoding nontagged (pcDNA3.11 backbone; Thermo
Fisher Scientific), GFP-tagged (pEGFP-C2 backbone; ClonTech), and
recombinant bacterial-expression [pBH4 backbone (Merino-Gracia et
al., 2016b)] versions were built as well by PCR and restriction cloning.
BiP-DIR comprised BiP amino acids 1-308. 3XFLAG-tagged versions
were obtained by using IVA cloning (García-Nafría et al., 2016) with
pcDNA3.11 plasmids as templates. pcDNA3.1-HA-CB1R, pcDNA3.1-
CB1R-myc, CB1R-Rluc, CB1R-GFP, and pcDNA3.1-A1R constructs had
been generated previously in our laboratory. Single phosphomimetic
mutants of CB1R–carboxyl-terminal domain (CTD), as well as the
CB1R-S452D-Rluc construct, were obtained through QuickChange mu-
tagenesis with the aforementioned plasmids as templates. pcDNA3.1-
CB2R was provided by Cristina Sánchez (Complutense University of
Madrid) and used to construct the corresponding Y2H vector. pCEFL-
GFP and pCEFL-GFP-GRK2 plasmids were given by J. Silvio Gutkind
(University of California San Diego). All constructs were validated by
Sanger sequencing before use.
Y2H. Screening of the library was performed following the manufac-
turer’s instructions (MatchMaker system, TaKaraBio). Plasmids of posi-
tive transformants were isolated and subsequently sequenced by
standard procedures. Directed Y2H experiments were conducted as pre-
viously reported (Merino-Gracia et al., 2016a). Yeasts were transformed
with plasmids containing the GAL4 binding domain and the GAL4 acti-
vation domain following a lithium acetate-based method. Double trans-
formants were placed on Leu/Trp/His-deficient plates in the presence of
12 mM 3-aminotriazole (triple dropout plates) as well as only Leu/Trp-
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deficient plates. Interacting proteins expressed within the same yeast
allowed colonies that could rescue growth in triple-dropout plates and
were capable to hydrolyze X-Gal.
Protein expression and purification. pBH4 plasmids encoding His6-
tagged BiP, BiP-IR (amino acids 497-654), or CB1R-CTD (amino acids
400-472) were used to transform competent BL21 DE3 Escherichia coli.
Typically, 2 L of bacterial culture in 2xYT (16 g/L tryptone, 10 g/L yeast
extract, 5 g/L NaCl, pH 7.0) was used for recombinant protein expres-
sion. Protein expression was induced by addition of 0.5 mM isopropyl 1-
thio-b -D-galactopyranoside (Panreac Química SAU) and incubation
overnight at 30°C with 250 rpm aeration rate. Bacterial cells were pel-
leted and frozen at20°C until used for protein purification.
Bacterial cell lysis was conducted in ice-cold lysis buffer (100 mM
Tris-HCl, 100 mM NaCl, 10 mM imidazole, pH 7.0) with continuous
shaking in the presence of protease inhibitors (1mg/ml aprotinin, 1mg/
ml leupeptin, 200 mM PMSF), 0.2 g/L lysozyme, and 5 mM b -mercapto-
ethanol, followed by four cycles of sonication on ice. The cell lysate was
clarified by centrifugation at 10,000  g and filtration through porous
paper. Recombinant His6-tagged proteins were sequentially purified on
a nickel-nitrilotriacetic acid affinity column. After extensive washing (50
mM Tris, 100 mM NaCl, 25 mM imidazole, pH 7.0), proteins were eluted
with elution buffer (50 mM Tris, 100 mM NaCl, 250 mM imidazole, pH
7.0; supplemented with protease inhibitors). Protein purity was con-
firmed by SDS-PAGE and Coomassie Brilliant Blue or Silver staining.
Pure protein solutions were concentrated by centrifugation in Centricon
tubes (Millipore).
Fluorescence polarization. His6-tagged CB1R-CTD (amino acids
400-472) was labeled with 5-(iodoacetamido)fluorescein (5-IAF) by
standard procedures. Briefly, the FITC dye was dissolved in DMSO, and
the labeling reaction was performed in sodium bicarbonate buffer, pH
9.0, with a threefold molar excess of dye for 1 h at 25°C, protected
from light. Subsequently, a 1.00 Da cutoff dialysis membrane was
used to eliminate nonreacted 5-IAF compound. After extensive dialy-
sis, the concentration of the labeled peptide was calculated using the
value 68,000 cm1 M1 as the molar extinction coefficient of the dye
at pH 8.0 at 494 nm. Saturation binding experiments were performed
essentially as described previously (Merino-Gracia et al., 2016a) with
a constant concentration of 100 nM 5-IAF-CB1R-CTD. The fluores-
cence polarization values obtained were fitted to the equation (FP –
FP0) = (FPMax – FP0)[BiP or BiP-IR]/(Kd 1 [BiP or BiP-IR]), where
FP is the measured fluorescence polarization, FPMax is the maximal
fluorescence polarization value, FP0 is the fluorescence polarization
in the absence of added BiP or BiP-IR, and Kd is the dissociation con-
stant as determined with GraphPad Prism version 8.0.1 (GraphPad
Software). FP was expressed as milli-FP units (mFP; net FP  1000).
Each representative curve shown is the mean of three internal
replicates.
Cell culture, transfection, and incubation. The HEK-293T cell line
was obtained from the American type Culture Collection. Cells were
grown in DMEM supplemented with 10% FBS (Thermo Fisher
Scientific), 1% penicillin/streptomycin, 1 mM Na-pyruvate, 1 mM L-glu-
tamine, and essential medium nonessential amino acids solution (diluted
1/100) (all from Invitrogen). Cells were maintained at 37°C in an atmos-
phere with 5% CO2 in the presence of the selection antibiotic (zeocin at
0.22mg/ml, Thermo Fisher Scientific), and were periodically checked for
the absence of mycoplasma contamination. Cell transfections were con-
ducted with polyethyleneimine (Polysciences) in a 4:1 mass ratio to
DNA according to the manufacturer’s instructions. Double transfec-
tions were performed with equal amounts of the two plasmids. In all
cases, 48 h after transfection, cells were washed twice in quick suc-
cession, detached, and harvested for further procedures. To control
cell number, protein concentration in the samples was determined
with a Bradford assay kit (Bio-Rad).
Drug treatments to assess CB1R-evoked signaling were conducted as
follows. A 10-cm-diameter plate of transfected cells was trypsinized and
seeded on a 6-well plate at a density of 0.75 106 cells per well. Six hours
later, cells were serum-starved overnight. Then, WIN-55212-2 (Tocris
Bioscience; 100 nM final concentration) or vehicle (DMSO, 0.1% v/v final
concentration) was added for 5, 10, or 15min. Gaq/11 inhibition was
achieved by adding YM-254890 (Focus Biomolecules; 1mM final concen-
tration) or vehicle (DMSO, 0.1% v/v final concentration) 30min before
WIN-55212-2 (100 nM final concentration) or vehicle (DMSO, 0.1% v/v
final concentration). All incubations were conducted in triplicate. Cells
were subsequently washed with ice-cold PBS, snap-frozen in liquid
nitrogen, and harvested at80°C for Western blot analyses.
In situ proximity ligation assay (PLA). BiP-CB1R complexes were
detected by using the Duolink In Situ PLA Detection Kit (Sigma-
Aldrich) following the manufacturer’s instructions. Synaptosomal prepa-
rations were incubated with a rabbit-anti-CB1R antibody (1:500,
Frontier-Institute, #CB1-Rb-Af530) and a mouse anti-GRP78/BiP anti-
body (1:500, Santa Cruz Biotechnology, #sc-376768). Negative controls
were performed with just one primary antibody. Ligations and amplifi-
cations were performed with In Situ Detection Reagent Red (Sigma-
Aldrich), and coverslips were mounted in DAPI-containing mounting
medium. Samples were analyzed with a Leica SP2/SP8 confocal micro-
scope (Leica Microsystems). For each FOV, a stack of two channels (one
per staining) and 9-13 Z stacks with a step size of 0.3mm were acquired
with a 63 oil-immersion objective and processed with ImageJ software
(National Institutes of Health). Representative images for each condition
were prepared for figure presentation by applying color adjustments uni-
formly with Adobe Photoshop version CS6.
For PLA imaging in brain sections, mice were deeply anesthetized
and immediately perfused transcardially with PBS followed by 4% PFA/
PB. Brains were removed and postfixed overnight in the same solution,
cryoprotected by immersion in 10%, 20%, 30% gradient sucrose (24 h
for each sucrose gradient) at 4°C, and then frozen in dry ice-cooled
methylbutane. Serial coronal or sagittal cryostat sections (30-mm-thick)
through the whole brain were collected in cryoprotective solution and
stored at 20°C until PLA experiments were performed. Immediately
before the assay, mouse brain sections were mounted on glass slides,
washed in PBS, permeabilized with PBS containing 0.01% Triton X-100
for 10min, and successively washed with PBS. Interactions were detected
with Duolink In Situ PLA Detection and In Situ Detection Reagent
Red Kits. A mixture of the primary antibodies [mouse anti-GRP78/
BiP antibody (1:100, Santa Cruz Biotechnology, #sc-376768) and
rabbit anti-CB1R antibody (1:100, Thermo Fisher Scientific, #PA1-
745)] was used. Samples were analyzed in a Leica SP2 confocal
microscope (Leica Microsystems) equipped with an apochromatic
63 oil-immersion objective (1.4 numerical aperture), and a 405 nm
and a 561 nm laser lines. For each FOV, a stack of two channels (one
per staining) and 9-13 Z stacks with a step size of 1 mm were
acquired. Images were opened and processed with ImageJ software
(National Institutes of Health). Quantification of cells containing
one or more red dots versus total cells (blue nuclei) was determined
by using the Fiji package (https://imagej.net/software/fiji/). Nuclei
and red dots were counted on the maximum projections of each
image stack. After getting the projection, each channel was proc-
essed individually. The blue nuclei and red dots were segmented by
filtering with a median filter, subtracting the background, enhanc-
ing the contrast with the Contrast Limited Adaptive Histogram
Equalization plug-in, and finally applying a threshold to obtain the
binary image and the regions of interest.
Bioluminescence resonance energy transfer (BRET). HEK-293T cells
growing in 6-well plates were transiently cotransfected with a constant
amount of cDNA encoding the receptor fused to Rluc protein and with
increasingly amounts of GFP-BiP-IR. To quantify protein-GFP expres-
sion, cells (20mg total protein) were distributed in 96-well microplates
(black plates with a transparent bottom) and the fluorescence was read
in a Fluostar Optima fluorimeter (BMG Labtech) equipped with a high-
energy xenon flash lamp using a 10 nM bandwidth excitation filter at
410 nm for protein-GFP reading. Protein-fluorescence expression was
determined as fluorescence of the sample minus the fluorescence of cells
expressing only the BRET donor. For BRET measurements, cells (20mg
of protein) were distributed in 96-well microplates (Corning 3600,
White plates; Sigma) and BRET signal was collected 1min after addition
of 5 mM DeepBlueC (Invitrogen) using a Mithras LB 940 reader
(Berthold Technologies) that allows the integration of the signals
detected in the short-wavelength filter at 400 nm and the long-
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wavelength filter at 510 nm. To quantify receptor-Rluc expression, lumi-
nescence readings were also performed after 10min of adding 5 mM
DeepBlueC (Invitrogen). The net BRET is defined as [(long-wavelength
emission)/(short-wavelength emission)] – Cf where Cf corresponds to
[(long-wavelength emission)/(short-wavelength emission)] for the Rluc
construct expressed alone in the same experiment. BRET is expressed as
milli BRET units (mBU; net BRET  1000). In BRET curves, BRET was
expressed as a function of the ratio between fluorescence and lumines-
cence (GFP/Rluc). To calculate maximal BRET from saturation curves,
data were fitted using a nonlinear regression equation and assuming a
single phase with GraphPad Prism software version 8.0.1. Each represen-
tative curve shown is the mean of three internal replicates.
Western blot and coimmunoprecipitation. Samples for Western blot-
ting were prepared on ice-cold lysis buffer (50 mM Tris-HCl, 1 mM
EDTA, 1 mM EGTA, 0.1% Triton X-100, 50 mM NaF, 10 mM Na-glycero-
phosphate, 5 mM Na-pyrophosphate, 1 mM Na-orthovanadate, pH 7.5).
Cell lysates were clarified by centrifugation at 12,000  g for 15min (4°
C), and total protein was quantified using the Bradford assay. Then, 5-20
mg aliquots of total protein, boiled for 5min at 95°C and prepared in 5
Laemmli sample buffer, were resolved by using SDS-PAGE and trans-
ferred to PVDF membranes. Membranes were blocked with 5% defatted
milk (w/v) or 5% BSA (w/v) in TBS-Tween-20 (0.1%) for 1 h and incubated
overnight with the following antibodies and dilutions: anti-phospho-ERK1/
2 (1:1000, CST, #9101), anti-ERK1/2 (1:1000, CST, #4696), anti-phospho-
p70S6K (1:1000, CST, #9206), anti-phospho-CREB (1:1000, CST, #9198),
anti-BiP (1:1000, Sigma-Aldrich, #G8918), anti-GFP (1:1000, Thermo
Fisher Scientific, #MA5-15256), anti-a-tubulin (1:10,000, Sigma-Aldrich,
#T9026), anti-b -actin (1:10,000, Sigma-Aldrich, #A5441), anti-FLAG M2
(1:1000, Sigma-Aldrich, #F3165), anti-HA (1:1000, CST, #3724S), and anti-
calnexin (1:1000, Santa Cruz Biotechnology, #SC-6465). All antibodies were
prepared in TBS-Tween-20 (0.1%) with 5% BSA (w/v). Membranes were
then washed 3 times with TBS-Tween-20 (0.1%), and HRP-labeled second-
ary antibodies, selected according to the species of origin of the primary
antibodies (Sigma-Aldrich, #NA-931-1 and #NA-934V), were added for 1 h
at a 1:5000 dilution in TBS-Tween-20 (0.1%) at room temperature. Finally,
protein bands were detected by incubation with an enhanced chemilumi-
nescence reagent (Bio-Rad), and densitometric analysis of the relative
expression of the protein of interest versus the corresponding loading con-
trol was performed with ImageJ software. Western blot images were
cropped for clarity. Electrophoretic migration of molecular weight markers
is depicted on the left-hand side of each blot.
For coimmunoprecipitation experiments, 48 h after transfection,
cells were lysed on ice-cold GST buffer (50 mM Tris-HCl, 10% glycerol
v/v, 100 mM NaCl, 2 mM MgCl2, 1% v/v NP-40, pH 7.4), supplemented
with protease inhibitors. Cell lysates were clarified by centrifugation at
12,000  g for 15min (4°C), and total protein was quantified with
Bradford assay; 20 mg aliquots were collected to check for transfection
levels (whole-cell lysates), and 1mg of total protein was incubated with
20ml of HA-agarose beads (Thermo Fisher Scientific, #26181) or FLAG
M2 agarose beads (Sigma-Aldrich, #A2220) for 2-4 h at 4°C with a final
protein concentration of 1mg/ml. Beads were subsequently washed 3
times with lysis buffer and eluted with 30 ml of 2 Laemmli Sample
Buffer without b -mercaptoethanol and 5min of sample boiling; 10
ml of the elution was further analyzed by Western blotting as previ-
ously described. GFP immunoprecipitation was performed analo-
gously, with a preclarification step on 30 ml of Protein A/G (GE
Healthcare, #17061801), followed by overnight incubation of the
remaining supernatant with 1 mg of anti-GFP antibody (produced
in-home), and 2-4 h of incubation with 30 ml of Protein A/G mix-
ture. The rest of the steps were identical to those mentioned above.
Dynamic mass redistribution (DMR). The cell-signaling signature was
determined using an EnSpire Multimode Plate Reader (PerkinElmer) by a
label-free technology. Cellular mass movements induced on receptor activa-
tion were detected by illuminating the underside of the biosensor with poly-
chromatic light and measured as changes in wavelength of the reflected
monochromatic light that is a sensitive function of the index of refraction.
The magnitude of this wavelength shift (herein measured in picometers) is
directly proportional to the amount of DMR. Briefly, 24 h before the assay,
cells were seeded at a density of 10,000 cells per well in 384-well sensor
microplates with 30ml growth medium and cultured for 24 h (37°C, 5%
CO2) to obtain 70%-80% confluent monolayers. Previous to the assay, cells
were washed twice with assay buffer (HBSS with 20 mM HEPES, pH 7.15)
and incubated for 2 h in 30ml per well of assay buffer with 0.1% DMSO in
the reader at 24°C. Hereafter, the sensor plate was scanned, and a baseline
optical signature was recorded before adding 10ml of the test compound
dissolved in assay buffer containing 0.1% DMSO. Then, DMR responses
were monitored along time, and kinetic data were analyzed using EnSpire
Workstation Software version 4.10. Each representative curve shown is the
mean of three internal replicates.
Phosphoprotein array. Cells transfected with CB1R-GFP and BiP-IR
(or control) plasmids were treated with WIN-55212-2 (100 nM final con-
centration) or vehicle (DMSO, 0.1% v/v final concentration) as described
above for 5 and 15min. Samples from two independent experiments
were processed separately by using 350mg of total protein per experi-
mental condition, following the instructions of the Proteome Profiler
Human Phospho-Kinase Array Kit (R&D Systems, Bio-techne,
#ARY003C). Densitometric analysis of the relative phosphorylation lev-
els versus the corresponding housekeeping controls and between WIN-
55212-2/vehicle treatments was performed with ImageJ software and the
Protein Array Analyzer toolset.
Cellular and subcellular fraction preparations. Membrane prepara-
tions for G-protein-coupling assays were obtained from HEK-293T-cell
pellets or adult mouse-hippocampus tissue specimens. Frozen samples
were thawed at 4°C and homogenized with a glass/Teflon grinder (IKA
labortechnik), 10 strokes at maximum speed, in 30 volumes of homoge-
nization buffer (250 mM sucrose, 50 mM Tris-HCl, 1 mM EGTA, 3 mM
MgCl2, 1 mM DTT, pH 7.4). The homogenates were centrifuged at
1100 g for 10min at 4°C. The pellets were discarded, and the superna-
tants were recentrifuged at 40,000  g for 10min at 4°C. The resultant
pellets were resuspended in 20 volumes of ice-cold centrifugation buffer
(50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 1 mM DTT, pH 7.4) with a
glass stick and recentrifuged at 40,000  g for 10min at 4°C. The pellets
obtained were then resuspended in 5 volumes of centrifugation buffer.
Protein content was determined by the Bradford method. Finally, ali-
quots of 0.5, 1.0, and 2.0mg protein were centrifuged at 21,000  g for
15min at 4°C. The supernatant layer was carefully discarded, and the
pellets were stored at80°C until assayed.
Total, cytosolic, and ER fractions from hippocampus, cortex, and
striatum of the adult mouse brain were obtained by lysing the corre-
sponding regions through sonication in 2 ml of ice-cold MTE buffer
(270 mM D-mannitol, 10 mM Tris-HCl, 0.1 mM EDTA, pH 7.4). Tissue
extracts were centrifuged (1400  g, 10min, 4°C), and the supernatant
(total cell lysate) was recentrifuged (15,000  g, 10min, 4°C) to separate
the pelleted mitochondrial crude fraction. Isolation of ER from cytosol
was achieved by loading the sample in a sucrose gradient (2 M - 1.5 M -
1.3 M) and conducting an ultracentrifugation step (152,000  g, 70min,
4°C). The ER fraction appears as a band at the 1.5 M/1.3 M sucrose inter-
phase, while the cytosolic fraction remains at the top of the tube. Both
fractions were collected, in the case of the ER with the aid of a syringe
with a 20G needle, and the ER fraction was further purified by an addi-
tional ultracentrifugation step (126,000  g, 45min, 4°C). The ER-con-
taining pellet was resuspended in 100ml of PBS and immediately frozen.
Likewise, aliquots of total cell lysate and cytosolic fractions were col-
lected throughout the process and immediately frozen. Samples were
kept at80°C for Western blot analysis.
Striatal, hippocampal, and cortical synaptosomes were isolated from
adult CB1R-KO mice and CB1R-WT control littermates, plated on poly-
L-lysine-covered coverslips, fixed in 4% PFA, and characterized as
described previously (Martín et al., 2010). PLA assays were conducted as
described above.
Antibody-capture [35S]GTPgS scintillation proximity assay. Specific
activation of different subtypes of Ga protein subunits (Gai1, Gai2,
Gai3, Gao, Gaq/11, Gas, Gaz, and Ga12/13) was determined by using a
homogeneous protocol of [35S]GTPgS scintillation proximity assay
coupled to the use of the following antibodies: mouse monoclonal anti-
Gai1 (1:20, Santa Cruz Biotechnology, #sc-56536), rabbit polyclonal
anti-Gai2 (1:20; Santa Cruz Biotechnology, #sc-7276), rabbit poly-
clonal anti-Gai3 (1:30, Antibodies on-line, #ABIN6258933), mouse
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monoclonal anti-Gao (1:40, Santa Cruz Biotechnology, #sc-393874), mouse
monoclonal anti-Gaq/11 (1:20, Santa Cruz Biotechnology, #sc-515689), rab-
bit polyclonal anti-Gas (1:20, Santa Cruz Biotechnology, #sc-383), rabbit
polyclonal anti-Gaz (1:20, Santa Cruz Biotechnology, #sc-388), and rabbit
polyclonal anti-Ga12/13 (1:20 Santa Cruz Biotechnology, sc-28588). [
35S]
GTPgS binding was measured in 96-well isoplates (PerkinElmer Life
Sciences) and a final volume of 200ml containing 1 mM EGTA, 3 mM
MgCl2, 100 mM NaCl, 0.2 mM DTT, 50 mM Tris-HCl, pH 7.4, 0.4 nM [
35S]
GTPgS, 10mg of protein per well, and different concentrations of GDP
(between 50 and 100 mM) depending on the Ga subunit subtype tested. At
the end of the 2 h incubation period (at 30°C), 20ml of 1% Igepal plus 0.1%
SDS was added to each well, and plates were incubated at 22°C for 30min
with gentle agitation. The specific antibody for the Ga subunit of interest
was then added to each well before an additional 90 min incubation period
at room temperature. Polyvinyltoluene SPA beads coated with protein A
(PerkinElmer) were then added (0.75mg of beads per well), and plates were
incubated for 3 h at room temperature with gentle agitation. Finally, plates
were centrifuged (5min at 1000  g), and the bound radioactivity was
detected on a MicroBeta TriLux scintillation counter (PerkinElmer). To
determine their effect on [35S]GTPgS binding to the different Ga subunit
subtypes in the different experimental conditions, a single submaximal con-
centration (10 mM) of WIN-55212-2 was used, either alone or in the pres-
ence of the CB1R antagonist O-2050 (10 mM) as control. Nonspecific
binding was defined as the remaining [35S]GTPgS binding in the presence
of 10 mM unlabeled GTPgS. For each Ga protein, specific [35S]GTPgS
binding values were transformed to percentages of basal [35S]GTPgS bind-
ing values (those obtained in the presence of vehicle).
Determination of cAMP concentration. Homogeneous time-resolved
fluorescence energy transfer assays were performed using the Lance
Ultra cAMP kit (PerkinElmer). HEK-293T cells (1000 per well), growing
in medium containing 50 mM zardeverine, were incubated in triplicate
for 15min in white ProxiPlate 384-well microplates (PerkinElmer) at 25°
C with vehicle orWIN-55212-2 (100 nM final concentration) before add-
ing vehicle or forskolin (0.5 mM final concentration) and incubating for
15 additional minutes. Fluorescence at 665 nm was analyzed on a
PHERAstar Flagship microplate reader equipped with a homogeneous
time-resolved fluorescence optical module (BMG Lab Technologies).
Animals. All the experimental procedures used were performed in
accordance with the guidelines and approval of the Animal Welfare
Committees of Universidad Complutense de Madrid and Comunidad
de Madrid, as well as of Universitat de Barcelona and Generalitat de
Catalunya, and in accordance with the directives of the Spanish
Government and the European Commission. BiP1/ (herein referred to
as BiP-HET) mice were purchased from The Jackson Laboratory
(#019549). We also used CB1R
floxed/floxed (herein referred to as CB1R-
floxed) mice, CB1R
floxed/floxed;CMV-Cre (herein referred to as CB1R-KO)
mice, conditional CB1R
floxed/floxed;Nex1-Cre (herein referred to as Glu-
CB1R-KO) mice, and conditional CB1R
floxed/floxed;Dlx5/6-Cre (herein
referred to as GABA-CB1R-KO) mice (Monory et al., 2006); as well as
Stop-CB1R, Stop-CB1R
EIIa-Cre (herein referred to as CB1R-RS) mice, con-
ditional Stop-CB1R
Nex1-Cre (herein referred to as Glu- CB1R-RS) mice,
and conditional Stop-CB1R
Dlx5/6-Cre (herein referred to as GABA-CB1R-
RS) mice, to allow CB1R gene-expression rescue from a CB1R-null back-
ground (Ruehle et al., 2013; De Salas-Quiroga et al., 2015). Animal
housing, handling, and assignment to the different experimental groups
were conducted as described previously (Ruiz-Calvo et al., 2018).
Adequate measures were taken to minimize pain and discomfort of the
animals.
ISH histochemistry. For ISH histochemistry, 14-mm-thick coronal
whole-brain tissue sections were obtained from adult C57BL/6 mice
(Janvier Laboratories), cut on a microtome-cryostat (Microm HM500 OM),
thaw-mounted on 3-aminopropyltriethoxysilane-coated slides (Sigma-
Aldrich), and kept at 20°C until further processing. The oligonucleotides
complementary to the mRNAs encoding BiP, CB1R, and GABAergic or
glutamatergic markers are listed in Table 1. Oligonucleotides for each
mRNA were labeled at their 39-end by using [a-33P]dATP (3000Ci/mmol,
Hartmann Analytic). Labeled probes were purified on ProbeQuant G-50
Micro Columns (GE Healthcare). ISH histochemistry procedures were per-
formed as described previously (Sanabra and Mengod, 2011). For autoradi-
ography, hybridized sections were exposed to Biomax-MR (Kodak) films
for 1-10d at70°C with intensifying screens. Double in situ-hybridized sec-
tions were processed as described previously (Reyes-Irisarri et al., 2007).
They were exposed in the dark for 4-6weeks at 4°C. Images from autor-
adiograms were obtained by using a Wild 420 macroscope (Leica
Microsystems) equipped with a digital camera (DXM1200 F, Nikon) and
ACT-1 Nikon software. Microphotography was performed with an
Olympus BX51 Stereologic Microscope (Olympus) equipped with a digital
camera (DP71, Olympus) or with a Carl Zeiss Axioplan microscope
equipped with an Olympus XC50 digital camera. Figures were assembled
using Adobe Photoshop (Adobe Systems). Only contrast and brightness
were uniformly adjusted to optimize images.
Behavioral tests. Adult male mice (3- to 4-month-old) were injected
intraperitoneally with vehicle (2% v/v DMSO in 1:18 v/v Tween-80/sa-
line solution) or 10mg/kg THC (THC Pharm). The “cannabinoid tet-
rad” was assessed, starting 30min after injection, following standard
guidelines (Metna-Laurent et al., 2017). First, the open-field test was
conducted for 10min in an arena of 70 70 cm. To evaluate anxiety-like
behaviors, the number of entries of the animal into the central part of
the arena (25 25 cm) relative to total ambulation was assessed, one
entry being counted when the animal had placed at least both forelimbs
in the square. Next, analgesia was assessed as the latency to paw licking
in the hotplate paradigm at a constant temperature of 52°C. Then, for
the catalepsy test, the animal was placed with both forelimbs leaning on
a bar situated at a height of 3.5 cm. Immobility was considered maximal
when the animal exceeded 60 s of immobility, and null when the im-
mobility time was lower than 5 s. In all cases, three attempts were
performed, and the maximal immobility time was selected as the repre-
sentative value. Finally, body temperature was measured with a rectal
thermometer and compared with the basal, pre-injection value.
The elevated plus maze test was evaluated 4 h after acute intraperito-
neal injection of vehicle or THC (10mg/kg). The maze consisted of a
cross-shaped plastic device with two opposite open arms (30-cm-long,
5-cm-wide) and two opposite closed arms (30-cm-long, 5-cm-wide, 16-
cm-tall walls), connected by a central structure (5 5 cm), and elevated
50 cm from the floor. Each mouse was placed in the center of the maze,
facing one of the open arms, and the exploratory behavior of the animal
was video-recorded for 5min. The number and duration of entries were
measured separately for the open arms and the closed arms. One arm
Table 1. Oligonucleotides used for ISH histochemistry
Oligonucleotide designation mRNA Accession number bp limits Oligonucleotide sequence
mCB1/1 Cannabinoid receptor 1 U22948.1 186-230 GATGGTACGGAAGGTGGTATCTGCAAGGCCGTCTAAGATCGACTT
mCB1/2 Cannabinoid receptor 1 U22948.1 556-600 ATAGCACCAGCAGGTTCTCCAGAACCGTGAAGGTGCCCAGGGTGA
mCB1/3 Cannabinoid receptor 1 U22948.1 1556-1601 CAGAGCCTCGGCAGACGTGTCTGTGGACACAGACATGGTCACCTT
mGRP78/1 78 kDa glucose-regulated protein (BiP) D78645.1 121-165 TCTTGTCCTCCTCCTCGGCCCGCACCGCGCCCAGCAGCAGCAACG
mGRP78/2 78 kDa glucose-regulated protein (BiP) D78645.1 1262-1306 ACACCAGCCTGGACAGCGGCACCATAGGCTACAGCCTCATCGGGG
mGRP78/3 78 kDa glucose-regulated protein (BiP) D78645.1 1996-2040 ATGTATCCTCTTCACCAGTTGGGGGAGGGCCTCCACTTCCATAGA
rmGAD65/1 Glutamic acid decarboxylase 65 NM_008078.2 421-465 CTTGTTTCCGATGCCGCCCGTGAACTTTTGGGCCACCTGGCACCA
rmGAD65/2 Glutamic acid decarboxylase 65 NM_008078.2 776-820 GCGTCAAAATTTCCTCCAGATTTTGCGGTTGGTCTGCCAATTCCC
rGAD/5 Glutamic acid decarboxylase 67 M76177.1 1601-1654 ATAGAGGTATTCAGCCAGCTCCAGGCATTTGTTGATCTGATTTTCAAATCCCAC
rVGluT1/1 Vesicular GluT1 transporter NM_053859.1 127-171 CAGGGCGCGCCCCGCCAGCTTCCGAAACTCCTCCTGCCGGAACTC
rVGluT1/2 Vesicular GluT1 transporter NM_053859.1 1756-1800 GTCCCGGACAGGGGGTGGGGGCCTTGGAGGCTGAACTGTGCTGTG
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Figure 1. BiP interacts with CB1R in vitro. A, Scheme of the Y2H experiment using CB1R-CTD (amino acids 408-472) as bait and a human cDNA library (.10
6 clones) as prey. One cDNA clone
(stained in blue) contained BiP/GRP78/Hspa5 amino acids 497-654 (BiP-IR). Diagram represents the main structural domains of BiP/GRP78/Hspa5 is shown. B, Scheme of the Y2H experiment
using fragments of CB1R-CTD or CB2R-CTD as bait and BiP-IR as prey. C, Fluorescence polarization-based protein–protein binding experiments using 5-IAF-labeled CB1R-CTD and increasing
amounts of unlabeled BiP-IR (top) or BiP (bottom). A representative experiment, including the gels of the purified proteins, is shown (n= 3). D, Coimmunoprecipitation experiments in HEK-
293T cells expressing fragments of GFP-CB1R-CTD and 3xFLAG-BiP-IR. Immunoprecipitation (IP) was conducted with anti-GFP antibody. WCL, Whole-cell lysate. A representative experiment is
shown (n= 3). E, Coimmunoprecipitation experiments in HEK-293T cells expressing HA-CB1R and 3xFLAG-BiP or 3xFLAG-BiP-IR. IP was conducted with anti-HA antibody (left) or anti-FLAG anti-
body (right). Asterisk indicates immunoglobulin heavy and light chains. A representative experiment is shown (n= 3). F, Coimmunoprecipitation experiments in HEK-293T cells expressing GFP-
CB1R-CTD WT or an S452D point mutant form, along with 3xFLAG-BiP-IR. IP was conducted with anti-GFP antibody. A representative experiment is shown (n= 3). G, BRET experiments in HEK-
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entry was registered when the animal had placed both forepaws in the
arm.
In all cases, animals were assigned randomly to the different treat-
ment groups, and all experiments were performed in a blinded manner
for genotype and pharmacological treatment. All tests were video-
recorded for subsequent blinded analysis using Smart3.0 version 3.00.6
Software (Panlab).
Experimental design and statistical analyses. Unless otherwise speci-
fied, data are presented as mean 6 SEM. Statistical comparisons were
conducted by one-way or two-way ANOVA with Tukey’s post hoc test,
or by Student’s t test, as indicated in each case. All datasets were tested
for normality (Kolmogorov–Smirnov’s test) and homoscedasticity
(Levene’s test) before analysis. For clarity, only p values, 0.05 were con-
sidered statistically significant. The sample size for each experiment was
estimated on the basis of previous studies conducted by our laboratories
using similar protein-interaction, cell-culture, brain-sample, and motor-
behavior approaches. Subsequent power analysis was conducted for each
parameter by using IBM SPSS software. The number of biological repli-
cates (e.g., number of mice, number of cell cultures) is provided in the
corresponding figure legends. The number of technical replicates (e.g.,
number of Y2H assays, number of incubations within each cell culture,
number of sections microscopically analyzed per mouse brain, number
of behavioral trials per mouse) is provided in the corresponding figure
legends or in the corresponding Materials and Methods subsections. All
the experiments conducted with animals are presented as dot plots.
Graphs and statistics were generated by GraphPad Prism version 8.0.1.
Results
BiP interacts with CB1R in vitro
To identify new CB1R-interacting intracellular proteins, we chal-
lenged the receptor’s CTD (amino acids 408-472) to a cDNA
library containing .106 different clones by means of a Y2H
system. One particular cDNA clone, comprising amino acids
497-654 of the protein BiP (hereafter “BiP-interacting region”
[BiP-IR]), provided an unequivocally positive outcome (Fig. 1A).
BiP, also known as GRP78 or Hspa5, belongs to the highly con-
served Hsp70 family of molecular chaperones. These proteins
consist of two different domains: an N-terminal nucleotide-bind-
ing domain with ATPase activity, and a C-terminal substrate-
binding domain (SBD). The SBD, in turn, is composed of a
b -sandwich domain (SBDb ) and an a-helical lid (SBDa), which
are interlinked by a hydrophobic stretch (Wieteska et al., 2017). It
is generally believed that ATP-assisted, BiP-mediated protein
refolding proceeds when hydrophobic peptides bind to a con-
served groove in the SBDb domain of BiP. Conversely, here, we
found that CB1R-CTD interacts essentially with the lid domain in
the absence of the groove. Specifically, according to the reported
structures (Yang et al., 2015, 2017), BiP-IR would span the entire
SBDa and two strands of the SBDb (Fig. 1A, bottom diagram).
We next aimed to validate the molecular specificity of the
interaction between CB1R-CTD and BiP-IR. First, by using
directed Y2H assays, we delimitated the BiP-IR-binding site to a
restricted 23 amino-acid stretch (residues 449-472) at the edge of
CB1R-CTD (Fig. 1B). Second, we found that the CTD of CB2R,
the GPCR with the highest sequence homology to CB1R, did not
bind BiP-IR (Fig. 1B). Third, as the phosphorylation state of spe-
cific S and T residues in the CTD of a GPCR can determine its
interaction with intracellular proteins, we challenged BiP-IR to
every possible single phosphomimetic mutant (S/T ! D) within
CB1R-CTD, and found that only the S452D point mutation,
which is precisely located in the last 23 amino-acid portion of
CB1R, impaired the association (Table 2). Fourth, we expressed
recombinant CB1R-CTD, BiP-IR, and BiP, and found that BiP
and BiP-IR bind CB1R-CTD with a similar high affinity, as meas-
ured by fluorescence polarization-based protein–protein binding
assays (Fig. 1C).
We subsequently conducted experiments in HEK-293T cells.
First, coimmunoprecipitation studies showed that (1) CB1R-
CTD, and specifically its 449-460 amino-acid stretch, was
sufficient to bind BiP-IR (Fig. 1D); (2) full-length CB1R also
interacted with both BiP and BiP-IR (Fig. 1E); and (3) BiP-IR
exhibited little association with the S452D point mutant of
CB1R-CTD (Fig. 1F). Second, BRET experiments conducted
with an Rluc-tagged version of CB1R also supported the protein–
protein interaction (Fig. 1G, top), and adding non–GFP-tagged
versions of BiP as competitors decreased the BRET peak only
when the BiP-IR was present (Fig. 1G, bottom) (n=3 experi-
ments; BiP-IR vs control: F(3,30) = 28.20, p, 0.0001, ANOVA;
BiP vs control: F(3,30) = 28.20, p, 0.0001, ANOVA; BiP-DIR vs
control: F(3,30) = 28.20, p= 0.3648, ANOVA). Moreover, there
was no overt binding between GFP-BiP-IR and CB1R-Rluc when
the S452D single mutation was introduced in the receptor (Fig.
1G, top).
Together, these data show that BiP interacts specifically with
CB1R in vitro, both in purified-protein assays and in HEK-293T
cells.
BiP modulates CB1R-evoked signaling
DMR is a powerful tool to assess the overall signal triggered by
the agonist-evoked activation of a particular receptor in living
cells (Fang et al., 2007). Indeed, we and others have previously
used DMR to investigate CB1R-evoked signaling (Viñals et al.,
2015; Moreno et al., 2018; Navarro et al., 2020). Here, by using
HEK-293T cells expressing CB1R, we found a well-defined and
saturating curve after adding the cannabinoid receptor-selective
agonist WIN-55212-2 (Fig. 2A). Of note, coexpression of full-
length BiP led to a strong inhibition of CB1R signaling (Fig. 2A)
but did not alter the agonist-evoked response of two other Gi/o-
coupled receptors (CB2R and adenosine A1 receptor) that were
used as controls (Fig. 3A). The effect of BiP on CB1R relied selec-
tively on BiP-IR, as expressing this region rendered a comparable
/
293T cells expressing CB1R-Rluc or CB1R-S452D-Rluc and increasing amounts of GFP-BiP-IR
(top; a representative experiment is shown; n= 3), together or not with nontagged versions
of BiP, BiP-IR, or BiP-DIR as competitors (bottom). **p, 0.01 from control vector by one-
way ANOVA with Tukey’s multiple comparisons test (n= 3).
Table 2. Effect of CB1R-CTD phosphomimetic mutants on CB1R-BiP interaction
a
Bait plasmid Prey plasmid Interaction
pGBT9 CB1R-CTD-S410D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S414D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-T418D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S425D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S429D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S441D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S448D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S452D pACT2 BiP-IR  (n= 3)
pGBT9 CB1R-CTD-T453D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-T460D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S462D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S464D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-T465D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-T467D pACT2 BiP-IR 1 (n= 3)
pGBT9 CB1R-CTD-S468D pACT2 BiP-IR 1 (n= 3)
aScheme of the Y2H experiment using every possible single phosphomimetic mutant (S/T!D) within CB1R-
CTD as bait, and BiP-IR as prey. Only one clone abrogated the interaction (CB1R-CTD-S452D).
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Figure 2. BiP modulates CB1R-evoked signaling. A, DMR experiments in HEK-293T cells expressing CB1R, together or not with BiP, BiP-IR, or BiP-DIR, and incubated with WIN-55212-2 (100
nM). A representative experiment is shown (n= 3). B, DMR experiments in HEK-293T cells expressing CB1R, together or not with BiP-IR, and incubated endocannabinoid (10mM; 2-AG, 2-arach-
idonoylglycerol; AEA, anandamide). A representative experiment is shown (n= 3). C, Coupling of CB1R to Gai/o proteins in membrane extracts from HEK-293T cells expressing CB1R, together or
not with BiP-IR. *p, 0.05 from basal (dashed line), or #p, 0.05 from control vector; one-sample Student’s t test or unpaired Student’s t test, respectively (n= 3). D, cAMP concentration in
HEK-293T cells expressing CB1R, together or not with BiP-IR. Cells were incubated first for 15min with vehicle or WIN-55212-2 (100 nM), and then for 15min with vehicle or forskolin (FSK; 500
nM). **p, 0.01 from vehicle, or ##p, 0.01 from FSK alone; two-way ANOVA with Tukey’s multiple comparisons test (n= 3). E, HEK-293T cells expressing CB1R, together or not with BiP-IR,
were incubated for 5 or 15min with vehicle or WIN-55212-2 (100 nM), and cell extracts were blotted on a phosphoprotein array. Two different times of membrane exposure are shown to allow
an appropriate visualization of the main proteins affected (framed spots). A representative experiment is shown (n= 2; membranes from vehicle-treated cells are omitted for clarity). Heat map
represents values of mean fold-activation by WIN-55212-2 over vehicle. F, Validation of some of the phosphoarray hits by conventional Western blotting in the same cell extracts used in D. A
representative experiment is shown (n= 2). G, Coupling of CB1R to non-Gai/o Ga proteins in membrane extracts from HEK-293T cells expressing CB1R, together or not with BiP-IR. *p, 0.05
from basal (dashed line), or ##p, 0.01 from control vector; one-sample Student’s t test or unpaired Student’s t test, respectively (n= 3). H, Western blotting of phospho-ERK in HEK-293T cells
expressing CB1R, and incubated for 5, 10, or 15min with vehicle or WIN-55212-2 (100 nM). Top, Cells were preincubated for 30min with vehicle or YM-254890 (1 mM). Bottom, Cells
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inhibition, and no change was found with BiP-DIR (Fig. 2A).
This effect was again subverted when the S452D point mutation
was inserted in CB1R (Fig. 3B), and was also evident, although
with a slower kinetics, when the endocannabinoids anandamide
and 2-arachidonoylglycerol were used as receptor agonists (Fig.
2B). Given the similar behavior of full-length BiP and BiP-IR, we
used only BiP-IR for further signaling experiments.
CB1R activation modulates multiple signaling pathways, with
cAMP/PKA, ERK, and PI3K/Akt/mTORC1 being the best char-
acterized (Pertwee et al., 2010; Nogueras-Ortiz and Yudowski,
2016). We thus aimed to dissect in detail the inhibitory effect of
BiP-IR on CB1R overall signaling observed in DMR assays. First,
we found that BiP-IR did not alter markedly the archetypical Gai/
o-coupling profile of CB1R (Fig. 2C) (n=3 experiments; Gai1-con-
trol vs Gai1-BiP-IR: t(25) = 1.730, p=0.0959, t test; Gai2-control vs
Gai2-BiP-IR: t(14) = 0.2886, p=0.7771, t test; Gai3-control vs
Gai3-BiP-IR: t(18) = 0.5927, p=0.5607, t test; Gao-control
vs Gao-BiP-IR: t(27) = 4.950, p, 0.0001, t test), nor affected the
WIN-55212-2-evoked reduction of forskolin-augmented cAMP
concentration (Fig. 2D) (n=3 experiments; control vs BiP-IR: ve-
hicle, F(2,12) = 45.98, p. 0.9999, ANOVA; forskolin, F(2,12) =
45.98, p. 0.9999, ANOVA; WIN-55212-2 1 forskolin, F(2,12) =
45.98, p=0.9893, ANOVA). Next, we analyzed the phosphoryla-
tion (activation) state of major cellular protein kinases by using a
phosphoprotein array. HEK-293T cells were transfected with the
same constructs used in the aforementioned DMR assays, and
subsequently treated with vehicle or WIN-55212-2. Among the
different pathways activated by the cannabinoid, BiP-IR preferen-
tially hampered the Akt/mTORC1 pathway (as inferred from
Akt1/2/3-T308, PRAS40-T246, and p70S6K-T389 phosphoryla-
tion) and the ERK pathway (as inferred from ERK1/2-T202/Y204
phosphorylation) (Fig. 2E). The WIN-55212-2-mediated activa-
tion of CREB, an archetypical convergent substrate of the Akt/
mTORC1 and ERK pathways, was also inhibited by BiP-IR (as
inferred from CREB-S133 phosphorylation). We confirmed this
BiP-mediated inhibition of CB1R-evoked signaling by analyzing
pERK1/2-T202/Y204, pp70S6K-T389, and pCREB-S133 with
conventional Western blotting (Fig. 2F). Accordingly, the
PI3K inhibitor LY294002 and the MEK1 inhibitor U0126
blunted the WIN-55212-2-evoked DMR signal (Fig. 3C).
To study how BiP selectively alters CB1R-mediated signaling
independently of Gai/o proteins, we evaluated the coupling of
the receptor to non-Gai/o G-proteins. Of note, we found that
CB1R also coupled to Gaq/11, and this association was impaired
by BiP-IR (Fig. 2G) (n= 3 experiments; Gaq/11-control vs
Gaq/11-BiP-IR: t(26) = 3.238, p= 0.0033, t test; Gas-control vs
Gas-BiP-IR: t(8) = 0.2220, p=0.8299, t test; Gaz-control vs Gaz-
BiP-IR: t(8) = 0.9241, p= 0.3825, t test; Ga12/13-control vs
Ga12/13-BiP-IR: t(18) = 0.3941, p= 0.6981, t test). Moreover,
WIN-55212-2-mediated ERK activation was mitigated by either
pharmacological blockade of Gaq/11 (with the drug YM-254890)
or genetic interference of Gaq/11 signaling (with a dominant-
negative GFP-GRK2 construct) (Andradas et al., 2016) (Fig. 2H).
Likewise, YM-254890 and dominant-negative Gaq/11 reduced
the WIN-55212-2-evoked DMR response (Fig. 2I). We next ana-
lyzed the coupling of CB1R to Gaq/11 in hippocampal extracts from
adult BiP1/ (hereafter BiP-HET) and BiP1/1 (hereafter BiP-WT)
mice [very early embryonic lethality occurs in BiP/ mice (Luo et
al., 2006).] In line with the aforementioned data from HEK-293T
cells, CB1R showed a preference for Gaq/11 coupling in BiP-HET
mice compared with their BiP-WT littermates (Fig. 2J) [BiP-WT
(n=5mice) vs BiP-HET (n=6mice): t(2) = 7.268, p=0.0184, t test].
Together, these data show that BiP-IR affects CB1R-evoked
signaling through the selective attenuation of an “alternative”
Gaq/11 protein-driven module, while leaving the “classical” Gai/o
protein-driven module essentially unaffected.
/
coexpressed control vector (GFP) or Gaq/11 dominant-negative vector (GFP-GRK2). A repre-
sentative experiment is shown (n= 3). I, DMR experiments in HEK-293T cells expressing
CB1R under the same experimental conditions as in G. A representative experiment is shown
(n= 3). J, Coupling of CB1R to Gaq/11 protein in hippocampal extracts from 3- to 4-month-
old BiP1/1 (BiP-WT) and BiP1/ (BiP-HET) mice. *p, 0.05 from basal (dashed line), or
#p, 0.05 from BiP-WT group; one-sample Student’s t test or unpaired Student’s t test,
respectively (n= 5 or 6 mice per group).
Figure 3. Controls of specificity of the CB1R-BiP DMR experiments. A, DMR experiments in
HEK-293T cells expressing CB2R, together or not with BiP, and incubated with the CB2R-selec-
tive agonist HU-308 (100 nM); or in HEK-293T cells expressing A1R, together or not with BiP,
and incubated with the A1R-selective agonist PIA (50 nM). A representative experiment is
shown (n= 3). B, DMR experiments in HEK-293T cells expressing CB1R-S452D, together or
not with BiP, and incubated with WIN-55212-2 (100 nM). A representative experiment is
shown (n= 3). C, DMR experiments in HEK-293T cells expressing CB1R and incubated with
WIN-55212-2 (100 nM) plus vehicle or U0126 (5 mM) or LY294002 (5 mM). A representative
experiment is shown (n= 3).
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CB1R-BiP complexes reside on GABAergic terminals of the
mouse brain
It is well established that CB1R resides largely on terminals of
GABAergic neurons (Marsicano and Lutz, 1999; Katona and
Freund, 2008). However, the precise neurochemical phenotype
of BiP-expressing cells remains unclear (compare Jin et al.,
2018). Hence, we analyzed the expression of BiP mRNA in
GABAergic versus glutamatergic neurons by ISH histochemistry.
BiP mRNA was localized throughout the mouse brain (Fig. 4A),
showing a more ubiquitous expression pattern than CB1R
mRNA (Fig. 4B). Of note, nearly all the hippocampal high CB1R
mRNA-expressing cells were also positive for BiP mRNA
[93.76 1.7% in the CA1/3 areas and 94.66 3.4% in the dentate
gyrus (DG); n=4 mice, t(6) = 0.2487, p=0.8119, t test] (Fig. 4C,D).
In the CA1/3 hippocampal areas, as reported for CB1R mRNA
(Marsicano and Lutz, 1999), BiP mRNA showed a high colocaliza-
tion with GAD65/67 mRNA (81.66 4.4% of the BiP-positive
cells coexpressed GAD65/67; n=4 mice) (Fig. 5A,B), while coloc-
alization with vGluT1 mRNA was hardly detectable in the scat-
tered BiP-expressing cells adjacent to the BiP/vGluT1 mRNA-
enriched pyramidal cell layer (0.46 0.7% of
the BiP-positive cells coexpressed vGluT1;
n=4 mice, t(6) = 18.48, p, 0.0001 from
BiP1GAD65/671 cells, t test) (Fig. 5C,D).
In the DG, the distribution of BiP mRNA
between disseminated GAD65/67 mRNA-
expressing neurons (Fig. 5A,B) and vGluT1
mRNA-expressing neurons (Fig. 5C,D) was
more balanced, although again with a pref-
erence toward inhibitory cells (47.06 9.9%
and 30.06 7.2% of the BiP-positive cells
coexpressed GAD65/67 or vGluT1, respec-
tively; n=4 mice, t(6) = 1.392, p=0.2133,
t test).
The most widely reported subcellular
localization of BiP is the ER lumen, while
CB1R is largely located at the plasma
membrane, and its CTD faces the cyto-
plasm since its biosynthesis starts on the
ER. To assess this apparent inconsistency,
we performed subcellular fractionation
experiments in mouse brain samples.
Analysis of hippocampal, striatal, and
cortical tissue extracts showed that BiP is
present not only in the ER but also in the
cytosolic fraction (Fig. 6A,B) [Hippo-
campus: cytosol (n=4 mice) vs ER (n=3
mice), F(2,8) = 21.50, p= 0.0004, ANOVA;
striatum: cytosol (n= 4 mice) vs ER (n=3
mice), F(2,8) = 6.232, p= 0.0234, ANOVA;
cortex: cytosol (n= 4 mice) vs ER (n=4
mice), F(2,9) = 2.858, p=0.9993,
ANOVA]. This observation supports the
notion that cytoplasmic BiP binds to
CB1R-CTD, and aligns with previous
reports showing that not all BiP functions
can be attributed to its interaction with
ER-resident proteins (Belfi et al., 1999;
Cha-Molstad et al., 2015; Shim et al.,
2018; Yoon et al., 2018), and that a popu-
lation of BiP molecules is found adjacent
to the plasma membrane (Tsai et al.,
2015). As the majority of CB1R resides at
the presynapse, where it controls neuro-
transmitter release (Piomelli, 2003), we
also evaluated whether CB1R-BiP complexes are present in this
subcellular location. PLA analyses revealed a pronounced posi-
tive signal in synaptosomes from the hippocampus, striatum,
and cortex of CB1R-WT mice, but not of CB1R-KO littermates
(Fig. 6C).
Next, to obtain a detailed neuroanatomical map of CB1R-BiP
protein complexes, we conducted in situ PLA assays on brain sli-
ces from various genetic mouse models of conditional loss or
gain of CB1R expression (Fig. 7A). We first used hippocampi
from conditional CB1R-KO models (Marsicano et al., 2002) (Fig.
7B-G). PLA experiments conducted on hippocampal sections
from control adult CB1R
floxed/floxed (hereafter CB1R-floxed) mice
showed that 63.26 4.7% and 62.96 11.2% of the cells contained
positive puncta in the DG and CA1, respectively (n= 6 or 7 fields
from 3 different mice, t(12) = 0.074, p= 0.9424, t test). This signal
was strongly reduced in sections from CB1R
floxed/floxed;CMV-Cre
(hereafter CB1R-KO) mice (DG: 14.86 5.0%; n= 6 fields from 3
different mice, F(3,23) = 109.6, p, 0.0001 from CB1R-floxed
mice, ANOVA. CA1: 18.86 4.5%; n=7 fields from 3 different
Figure 4. Expression of BiP and CB1R mRNA in the mouse brain. A, B, Representative autoradiographic images of coronal
sections from adult mouse brain showing the mRNA hybridization pattern of BiP (A) and CB1R (B). CA, Cornu ammonis; DG,
dentate gyrus; Str, striatum; Cx, cortex; Cb, cerebellum. C, Distribution of CB1R mRNA in the mouse hippocampus. Ci,
Representative dark field image from a section hybridized with 33P-labeled oligonucleotide probes for CB1R mRNA. A positive
signal is evident as clusters/accumulation of bright silver grains. Note the moderate signal on the pyramidal cell layer of CA
and the very intense signal on scattered cells in the various hippocampal layers. Cii, Ciii, Colocalization of CB1R mRNA and
BiP mRNA in cells of the stratum radiatum and stratum lacunosum moleculare of CA. Pyr, Pyramidal cell layer of CA. Civ, Cv,
Colocalization of CB1R mRNA and BiP mRNA in cells of the polymorphic layer (Pl). Gr, Granular cell layer. Sections were hybri-
dized with 33P-labeled probes for CB1R mRNA (signal visualized as clusters of bright silver grains in dark field images) and
with digoxigenin-labeled probes for BiP mRNA (signal visualized as dark precipitate in bright field images). Arrows point to
some double-labeled cells. D, Quantification of CB1R mRNA-positive cells that coexpress BiP mRNA (n= 4 mice per group).
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mice, F(3,24) = 40.86, p, 0.0001 from
CB1R-floxed mice, ANOVA). In condi-
tional KO mice in which the gene encod-
ing CB1R had been selectively deleted
from forebrain GABAergic neurons
(CB1R
floxed/floxed;Dlx5/6-Cre; hereafter GABA-
CB1R-KO), we found a notable decrease in
the percentage of cells expressing positive
dots (DG: 31.96 6.2%; n=7 fields from 3
different mice, F(3,23) = 109.6, p, 0.0001
from CB1R-floxed mice, ANOVA. CA1:
33.96 7.8%, n=7 fields from 3 different
mice, F(3,24) = 40.86, p, 0.0001 from
CB1R-floxed mice, ANOVA). In contrast,
sections from mice in which the gene
encoding CB1R had been selectively
deleted from dorsal telencephalic glutama-
tergic neurons (CB1R
floxed/floxed;Nex1-Cre;
hereafter Glu-CB1R-KO) displayed a simi-
lar pattern of PLA staining than their
CB1R-floxed counterparts (DG: 58.66
5.9%; n=7 fields from 3 different mice,
F(3,23) = 109.6, p=0.3052 from CB1R-
floxed mice, ANOVA. CA1: 60.86 1.1%;
n=7 fields from 3 different mice, F(3,24) =
40.86, p. 0.9999 from CB1R-floxed mice,
ANOVA). Comparable overall data were
obtained in sections from mouse striatum
(Fig. 8B,D) [CB1R-KO (n=7 fields from 3
different mice) vs CB1R-floxed (n=7 fields
from 3 different mice): F(3,23) =151.4,
p, 0.0001, ANOVA; GABA-CB1R-KO
(n = 7 fields from 3 different mice) vs
CB1R-floxed (n=7 fields from 3 different
mice): F(3,23) = 151.4, p, 0.0001, ANOVA;
Glu-CB1R-KO (n=6 fields from 3 different
mice) vs CB1R-floxed (n=7 fields from 3
different mice): F(3,23) = 151.4, p=0.0850,
ANOVA] and cortex (Fig. 8E,G) [CB1R-
KO (n=7 fields from 3 different mice) vs
CB1R-floxed (n=6 fields from 3 different
mice): F(3,22) = 48.30, p, 0.0001, ANOVA;
GABA-CB1R-KO (n=7 fields from 3 differ-
ent mice) vs CB1R-floxed (n=6 fields from
3 different mice): F(3,22) = 48.30, p=0.0006,
ANOVA; Glu-CB1R-KO (n=7 fields from
3 different mice) vs CB1R-floxed (n=6
fields from 3 different mice): F(3,22) = 48.30, p=0.6079, ANOVA].
We subsequently made use of a Cre-mediated, lineage-spe-
cific, CB1R gene expression-rescue strategy from a CB1R-null
background (hereafter Stop-CB1R mice) (De Salas-Quiroga et al.,
2015; De Giacomo et al., 2020a) (Fig. 7C-G). PLA assays in hip-
pocampal sections from these mice showed, as expected, a mar-
ginal CB1R-KO-like background signal (DG: 20.16 3.2%, CA1:
21.26 3.2%; n= 5 or 7 fields from 3 different mice, respectively;
t(10) = 0.5326, p= 0.6060, t test). In line with the data from condi-
tional KO mice, rescuing CB1R gene expression in Stop-CB1R
mice with a constitutive Cre recombinase (Stop-CB1R
EIIa-Cre,
hereafter, CB1R-RS) restored CB1R-BiP complexes to the levels
of control CB1R-floxed mice (DG: 59.66 5.5%, CA1: 58.56
5.8%; n=5 or 7 fields from 3 different mice, respectively; F(3,24) =
94.99, p, 0.0001, ANOVA; and F(3,22) = 121.6, p, 0.0001,
ANOVA, respectively). This effect was paralleled in brain sections
from conditionally rescued Stop-CB1R
Dlx5/6-Cre (hereafter, GABA-
CB1R-RS) mice [DG: 58.16 9.6%; n=7 fields from 3 different
mice; F(3,24) = 94.99, p= 0.9279 from CB1R-RS mice, ANOVA.
CA1: 56.96 5.5%; n=7 fields from 3 different mice; F(3,22) = 121.6,
p=0.8400 from CB1R-RS mice, ANOVA], but not from condition-
ally rescued Stop-CB1R
Nex1-Cre [hereafter, Glu-CB1R-RS mice (DG:
21.16 3.2%; n=7 fields from 3 different mice; F(3,24) = 94.99,
p, 0.0001 from CB1R-RS mice, ANOVA. CA1: 20.06 2.5%; n=7
fields from 3 different mice; F(3,22) = 121.6, p, 0.0001 from CB1R-
RS mice, ANOVA]. As in the aforementioned conditional KO
mouse experiments, these CB1R gene expression-rescue data in the
mouse hippocampus displayed a similar global pattern in the mouse
striatum (Fig. 8C,D) [Stop-CB1R (n=7 fields from 3 different mice)
vs CB1R-RS (n=7 fields from 3 different mice): F(3,22) = 230.5,
p, 0.0001, ANOVA; GABA-CB1R-RS (n=6 fields from 3 different
mice) vs CB1R-RS (n=7 fields from 3 different mice): F(3,22) =
230.5, p=0.3465, ANOVA; Glu-CB1R-RS (n=6 fields from 3 differ-
ent mice) vs CB1R-RS (n=7 fields from 3 different mice): F(3,22) =
230.5, p, 0.0001, ANOVA] and cortex (Fig. 8F,G) [Stop-CB1R
Figure 5. Colocalization of BiP mRNA with GAD65/67 or vGlut1 mRNA in the mouse hippocampus. A, Representative
mosaic superimages of sections from the adult mouse hippocampus that were hybridized with 33P-labeled probes for BiP
mRNA (signal visualized as clusters/accumulation of bright silver grains in the dark field image Ai) and with a mixture of
digoxigenin-labeled probes for GAD65 and GAD67 mRNAs (labeled cells showing dark precipitate in the bright field image
Aii). Higher-magnification images of cornu ammonis (CA; Aiii, Aiv) and dentate gyrus (DG; Av, Avi) are shown. Arrows point
to some double-labeled cells. Arrowheads point to some cells that express BiP mRNA but not GAD65/67 mRNA. B,
Quantification of BiP mRNA-positive cells that coexpress GAD65/67 mRNA (n= 4 mice per group). C, Representative mosaic
superimages of sections from the adult mouse hippocampus that were hybridized with 33P-labeled probes for BiP mRNA (sig-
nal visualized as clusters/accumulation of bright silver grains in the dark field image Ci) and with digoxigenin-labeled probes
for vGluT1 mRNA (labeled cells showing dark precipitate in the bright field image Cii). Higher-magnification images of CA
(Ciii, Civ) and DG (Cv, Cvi) are shown. Arrows point to some double-labeled cells. Arrowheads point to some cells that
express BiP mRNA but not vGluT1 mRNA. D, Quantification of BiP mRNA-positive cells that coexpress vGluT1 mRNA (n= 4
mice per group).
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(n=6 fields from 3 different mice) vs CB1R-RS (n=7 fields from 3
different mice): F(3,22) = 167.0, p, 0.0001, ANOVA; GABA-CB1R-
RS (n=7 fields from 3 different mice) vs CB1R-RS (n=7 fields
from 3 different mice): F(3,22) = 167.0, p=0.0620, ANOVA; Glu-
CB1R-RS (n=6 fields from 3 different mice) vs CB1R-RS (n=7
fields from 3 different mice): F(3,22) = 167.0, p, 0.0001, ANOVA].
Together, these data support the interaction between CB1R
and BiP in three key regions of the mouse brain, and, more spe-
cifically, a restricted occurrence of CB1R-BiP complexes in
GABAergic neurons.
BiP affects CB1R function in vivo
THC induces numerous behavioral changes in laboratory animals
and humans. The combination of hypolocomotion, analgesia, cat-
alepsy, and hypothermia, usually designated as the “cannabinoid
tetrad,” has evolved as a powerful tool
to identify pharmacological or genetic
interventions that target CB1R (Martin,
1986; Metna-Laurent et al., 2017).
Previous studies have shown that these
four behavioral traits rely selectively on
the activation of CB1R molecules located
on various populations of glutamatergic
or dopamine D1 receptor-expressing
projection neurons, but not on
GABAergic interneurons, thus allowing
a neurobiological correlate between
CB1R cellular expression and function
(Monory et al., 2007; De Giacomo et
al., 2020a). We studied the “cannabi-
noid tetrad” in BiP-HET and BiP-WT
littermates (Fig. 9A), and found that
acute THC injection (10 mg/kg, i.p.) eli-
cited the four archetypical effects of the
“cannabinoid tetrad” to the same extent in
BiP-HET and BiP-WT animals (Fig. 9, left
panels) [Hypolocomotion: BiP-WT-vehi-
cle (n=19 mice) vs BiP-WT-THC (n=17
mice), F(1,72) = 111.9, p, 0.0001,
ANOVA; BiP-HET-vehicle (n= 20 mice)
vs BiP-HET-THC (n=19 mice), F(1,72) =
111.9, p, 0.0001, ANOVA. Analgesia:
BiP-WT-vehicle (n=10 mice) vs BiP-
WT-THC (n=9 mice), F(1,35) = 32.93,
p=0.0059, ANOVA; BiP-HET-vehicle
(n=10 mice) vs BiP-HET-THC (n=10
mice), F(1,35) = 32.93, p=0.0030,
ANOVA. Hypothermia: BiP-WT-vehicle
(n=9 mice) vs BiP-WT-THC (n=9
mice), F(1,35) = 50.76, p=0.0012,
ANOVA; BiP-HET-vehicle (n=9 mice)
vs BiP-HET-THC (n=8 mice), F(1,35) =
50.76, p = ,0.0001, ANOVA. Catalepsy:
BiP-WT-vehicle (n=10 mice) vs BiP-
WT-THC (n=9 mice), F(1,35) = 124.5,
p, 0.0001, ANOVA; BiP-HET-vehicle
(n=9 mice) vs BiP-HET-THC (n=9
mice), F(1,35) = 124.5, p, 0.0001,
ANOVA]. In addition, following a 5 d
sustained treatment, BiP-HET and
BiP-WT mice developed a comparable
tolerance to THC (Fig. 9, right
panels) [Hypolocomotion: BiP-WT-
vehicle (n = 20 mice) vs BiP-WT-THC
(n = 17 mice), F(1,73) = 0.4632, p = 0.7219, ANOVA; BiP-
HET-vehicle (n = 20 mice) vs BiP-HET-THC (n = 20 mice),
F(1,73) =0.4632, p = 0.1704, ANOVA. Analgesia: BiP-WT-ve-
hicle (n = 10 mice) vs BiP-WT-THC (n = 9 mice), F(1,35) =
1.094, p = 0.9759, ANOVA; BiP-HET-vehicle (n = 10 mice) vs
BiP-HET-THC (n = 10 mice), F(1,35) = 1.094, p = 0.7068,
ANOVA. Hypothermia: BiP-WT-vehicle (n = 10 mice) vs
BiP-WT-THC (n = 8 mice), F(1,33) = 6.741, p = 0.7040,
ANOVA; BiP-HET-vehicle (n = 10 mice) vs BiP-HET-THC
(n = 9 mice), F(1,33) = 6.741, p = 0.0609, ANOVA. Catalepsy:
BiP-WT-vehicle (n = 10 mice) vs BiP-WT-THC (n = 9 mice),
F(1,35) = 7.437, p = 0.2262, ANOVA; BiP-HET-vehicle (n = 10
mice) vs BiP-HET-THC (n = 10 mice), F(1,35) = 7.437,
p = 0.2440, ANOVA].
Figure 6. Subcellular localization of BiP in the mouse brain. A, Western blotting of BiP in total-extract (T), cytosolic (C), and
ER fractions from the hippocampus, striatum, and cortex of 3- to 4-month-old WT mice. Calnexin was included as an ER-specific
marker. Representative blots from 2 mice are shown. B, Quantification of BiP levels in the C and ER fractions relative to BiP lev-
els in the T fraction. *p, 0.05, **p, 0.01 from the corresponding ER fraction by one-way ANOVA with Tukey’s multiple com-
parisons test (n= 3 or 4 mice per group). C, PLA experiments conducted on synaptosomal fractions isolated from the
hippocampus, striatum, and cortex of 3- to 4-month-old CB1R-WT and CB1R-KO mice. Representative images of hippocampal
(left column), striatal (middle column), and cortical (right column) synaptosomes, with CB1R-BiP complexes depicted in red, are
shown (n= 5 mice per group).
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As the CB1R-BiP complexes reside selectively on GABAergic
neurons (see above), it is not surprising that the deletion of a BiP
allele does not modify any of the classical “cannabinoid tetrad”
behavioral traits. Of note, anxiety-like behaviors induced by
cannabinoid intoxication have been shown to rely selectively on
the activation of CB1R molecules located on GABAergic inter-
neurons (Rey et al., 2012; De Giacomo et al., 2020a,b). Because
the open-field test of the “cannabinoid tetrad” can also be used
Figure 7. CB1R-BiP complexes reside on GABAergic terminals of the mouse hippocampus. A, PLA experiments were conducted on hippocampal sections from 3- to 4-month-old mice of dif-
ferent genotypes. Representative low-magnification image and selected regions for analysis are shown. Image credit: Allen Institute. In the rest of the panels, CB1R-BiP complexes are shown as
red dots, and nuclei are colored in blue by DAPI staining. B, Representative images of dentate gyrus (DG) sections from CB1R-floxed, CB1R-KO, GABA-CB1R-KO, and Glu-CB1R-KO mice. C,
Representative images of DG sections from Stop-CB1R, CB1R-RS, GABA-CB1R-RS, and Glu-CB1R-RS mice. D, Quantification of the number of cells containing one or more dots expressed as the
percentage of the total number of cells (DAPI-stained nuclei) in DG sections. **p, 0.01 from the corresponding CB1R-floxed group or the corresponding CB1R-RS group by one-way ANOVA
with Tukey’s multiple comparisons test (n= 6 or 7 fields from 3 different animals per group). E, Representative images of CA1 sections from CB1R-floxed, CB1R-KO, GABA-CB1R-KO, and Glu-
CB1R-KO mice. F, Representative images of CA1 sections from Stop-CB1R, CB1R-RS, GABA-CB1R-RS, and Glu-CB1R-RS mice. G, Quantification of the number of cells containing one or more dots
expressed as the percentage of the total number of cells (DAPI-stained nuclei) in CA1 sections. **p, 0.01 from the corresponding CB1R-floxed group or the corresponding CB1R-RS group by
one-way ANOVA with Tukey’s multiple comparisons test (n= 6 or 7 fields from 3 different animals per group).
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to define anxious phenotypes by evaluating the relative ambula-
tion of the animals across the center of the arena (Seibenhener
and Wooten, 2015), we conducted these analyses in our experi-
mental setting. A single THC injection reduced the ambulation
of the mice across the center of the arena equally in BiP-HET
and BiP-WT mice (Fig. 10A, left) [BiP-WT-vehicle (n=20 mice)
vs BiP-WT-THC (n=17 mice): F(1,73) = 32.35, p=0.0164,
ANOVA; BiP-HET-vehicle (n=20 mice) vs BiP-HET-THC
Figure 8. CB1R-BiP complexes reside on GABAergic terminals of the mouse striatum and cortex. A, PLA experiments were conducted on striatal and cortical sections from 3- to 4-month-old mice of differ-
ent genotypes. Representative low-magnification image and selected regions for analysis are shown. Image credit: Allen Institute. In the rest of the panels, CB1R-BiP complexes are shown as red dots, and
nuclei are colored in blue by DAPI staining. B, Representative images of striatal sections from CB1R-floxed, CB1R-KO, GABA-CB1R-KO, and Glu-CB1R-KO mice. C, Representative images of striatal sections from
Stop-CB1R, CB1R-RS, GABA-CB1R-RS, and Glu-CB1R-RS mice. D, Quantification of the number of cells containing one or more dots expressed as the percentage of the total number of cells (DAPI-stained nuclei)
in striatal sections. **p, 0.01 from the corresponding CB1R-floxed group or the corresponding CB1R-RS group by one-way ANOVA with Tukey’s multiple comparisons test (n=6 or 7 fields from 3 different
animals per group). E, Representative images of cortical sections from CB1R-floxed, CB1R-KO, GABA-CB1R-KO, and Glu-CB1R-KO mice. F, Representative images of cortical sections from Stop-CB1R, CB1R-RS,
GABA-CB1R-RS, and Glu-CB1R-RS mice. G, Quantification of the number of cells containing one or more dots expressed as the percentage of the total number of cells (DAPI-stained nuclei) in cortical sections.
**p, 0.01 from the corresponding CB1R-floxed group or the corresponding CB1R-RS group by one-way ANOVA with Tukey’s multiple comparisons test (n=6 or 7 fields from 3 different animals per group).
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(n=20 mice): F(1,73) = 32.35, p, 0.0001,
ANOVA]. However, after a 5 d continu-
ing THC treatment, the ambulation
across the center of the arena remained
lowered by acute THC in BiP-HET mice
but not in their BiP-WT littermates (Fig.
10A, right) [BiP-WT-vehicle (n= 20
mice) vs BiP-WT-THC (n= 18 mice):
F(1,74) = 20.54, p= 0.5226, ANOVA; BiP-
HET-vehicle (n=20 mice) vs BiP-HET-
THC (n=20 mice): F(1,74) = 20.54,
p, 0.0001, ANOVA].
To provide further support to the con-
trol of CB1R-mediated anxiety by BiP, we
used the elevated plus maze test, a widely
recognized measure of anxiety that served
originally to define the anxiogenic activity
of the CB1R pool located on GABAergic
neurons (Rey et al., 2012). We injected
BiP-WT and BiP-HET mice with vehicle
or THC (10mg/kg, i.p.), and found that
the drug induced only an anxiogenic
trend in BiP-WT mice but a significant
anxiogenic effect in BiP-HET littermates,
as evidenced by the decrease in both the
number of entries (Fig. 10B, left) [BiP-
WT-vehicle (n=27 mice) vs BiP-WT-
THC (n=20 mice): F(1,86) = 11.51,
p= 0.1471, ANOVA; BiP-HET-vehicle
(n=21 mice) vs BiP-HET-THC (n= 22
mice): F(1,86) = 11.51, p=0.0470,
ANOVA] and the time of permanence
(Fig. 10B, right) in the open arms of the
device [BiP-WT-vehicle (n=27 mice) vs
BiP-WT-THC (n= 20 mice): F(1,86) =
11.34, p=0.3385, ANOVA; BiP-HET-vehi-
cle (n=21 mice) vs BiP-HET-THC (n=22
mice): F(1,86) = 11.34, p=0.0155, ANOVA].
Together, these data support that BiP,
by interacting with CB1R on GABAergic
neurons, modulates anxiety-like behav-
iors on cannabinoid administration.
Discussion
Here, we show that BiP interacts specifi-
cally with CB1R-CTD. BiP is known to
interact with some GPCRs during their
folding (Siffroi-Fernandez et al., 2002;
Mizrachi and Segaloff, 2004; Langer et al.,
2008), and has been found associated to
melanocortin MC4 receptors at the
plasma membrane (Yoon et al., 2018).
The CB1R-BiP interaction occurs between
a short amino-acid stretch in the CB1R-
CTD and the BiP-SBDa domain. The lat-
ter domain, to our knowledge, has never
been implicated in the binding of BiP to
membrane receptors. As the protein-bind-
ing/refolding function of BiP is usually
ascribed to its SBDb domain (Yang et al.,
2015, 2017), we cannot rule out that addi-
tional proteins interact through this region
Figure 9. BiP does not affect CB1R-evoked hypolocomotion, analgesia, hypothermia, and catalepsy in vivo. A, Scheme of the experi-
ments. Vehicle or THC (10mg/kg, 1 i.p. injection per day) was administered for 5 d to 3- to 4-month-old BiP1/1 (BiP-WT) and
BiP1/ (BiP-HET) mice. The “cannabinoid tetrad” was evaluated on days 1 and 5, starting 30min after the corresponding acute-drug
injections. B, Ambulation (total distance traveled, cm) in the open-field test on day 1 (left) and day 5 (right). C, Analgesia (latency to
pain, s) in the hotplate test on day 1 (left) and day 5 (right). D, Hypothermia (change in body temperature, °C) as measured with a rec-
tal thermometer on day 1 (left) and day 5 (right). E, Catalepsy (latency to move, s) as measured on a horizontal bar on day 1 (left)
and day 5 (right). B-E: **p, 0.01 from the corresponding vehicle group; ##p, 0.01 from the BiP-WT-vehicle group; two-way
ANOVA with Tukey’s multiple comparisons test (B, n=17-20 mice per group; C-E, n=9 or 10 mice per group).
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onto the CB1R-BiP complexes. The BiP-interacting region in
CB1R partially overlaps with the putative C-terminal helix 9
of the receptor (Ahn et al., 2009), which might serve as an
axon-targeting signal and a potential protein–protein inter-
action site (Fletcher-Jones et al., 2019). How the synaptic
trafficking of CB1R could be controlled by BiP is therefore
an intriguing possibility that remains to be explored.
Additionally, the BiP-binding region of CB1R contains a spe-
cific phosphorylation site (S452) that regulates this protein–
protein interaction, and may conceivably participate in
agonist-induced receptor signaling and subsequent internal-
ization (Daigle et al., 2008). Indeed, a high-throughput phos-
phoproteomic study identified this phosphorylated residue
in the mouse brain (Wisniewski et al., 2010). The lack of
reported mutations in this BiP-binding region of CB1R
(https://gpcrdb.org), along with its evolutionary conserva-
tion, further supports its biological importance.
CB1R-evoked signaling is markedly
affected on BiP binding. This finding
contrasts with the subtle effect of
CRIP1a on CB1R/G-protein coupling
(Blume et al., 2015), and with the BiP-
mediated facilitation of melanocortin
MC4 receptor activation (Yoon et al.,
2018). Accruing evidence has linked ERK
and Akt/mTORC1 activation to various
key CB1R-evoked effects in the brain
(Rubino et al., 2007; Guegan et al., 2013;
Puighermanal et al., 2013; Blázquez et al.,
2020). However, the possible relevance of
Gaq/11 protein in CB1R neurobiological
action remains unclear (Diez-Alarcia et
al., 2016). Our data unveil an unprece-
dented functional coupling of CB1R sig-
naling to Gaq/11, as well as a selective
hampering effect of BiP on it. Inte-
restingly, regions analogous to CB1R helix
9, which overlaps with the BiP-binding
site, have been reported to act as Gaq/11-
binding sites in rhodopsin (Murakami
and Kouyama, 2008) and bradykinin B2
receptor (Piserchio et al., 2005). Thus, it is
conceivable that in CB1R the binding of
BiP constitutes a competitive steric
impediment to achieve Gaq/11 binding
and activation.
Our detailed mapping of CB1R-BiP
complexes in the mouse brain shows
that GABAergic neurons constitute the
foremost cell population expressing
these complexes. This is in line with a
previous high-throughput proteomic
study showing that BiP coimmunopre-
cipitates with CB1R in mouse
GABAergic neurons (Mattheus et al.,
2016). It is worth noting that, despite
their low CB1R/G-protein coupling
efficacy (Steindel et al., 2013),
GABAergic terminals contain large
amounts of CB1R (Marsicano and
Lutz, 1999; Katona and Freund, 2008)
likely displaying a high tonic activity
(Roberto et al., 2010). Given
its inhibitory role, we speculate that
BiP binding may represent a counterpoint to ensure a bal-
anced CB1R activity in the physiological control of glutama-
tergic/GABAergic neurotransmission. More specifically,
THC-elicited anxiety relies on mTORC1 activation on engage-
ment of CB1R on hippocampal GABAergic interneurons (Rey
et al., 2012; Puighermanal et al., 2013; De Giacomo et al.,
2020a,b). In addition, a role of Gaq/11 protein-coupled recep-
tors (e.g., serotonin 5-HT2C receptor) in the induction of anxi-
ety has been suggested (Mazzone et al., 2018). Thus, we
propose that the THC-evoked high-input activation of a re-
stricted Gaq/11-coupled pool of CB1R molecules located on
hippocampal GABAergic interneurons, via the mTORC1 sig-
naling axis, triggers anxiety-like behaviors, a process plausibly
controlled by BiP binding to CB1R at the presynapse. This
would provide an unprecedented mechanism for the spatially
selective control of CB1R signaling in the brain, and supports
Figure 10. BiP modulates CB1R-evoked anxiety in vivo. Anxiety-like behaviors were measured on an experimental scheme
similar to that shown in Figure 9A. A, Anxiety (normalized entries in the center, m1) in the open-field (OF) test on day 1
(left) and day 5 (right). Arenas (with their centers outlined in red) illustrating the ambulation of a representative animal per
group on day 5 are shown (bottom). B, Anxiety (left: number of entries in the open arms; right: time spent in the open arms,
%) in the elevated plus maze (EPM) test on day 1. A, B: *p, 0.05, **p, 0.01 from the corresponding vehicle group, or
#p, 0.05, ##p, 0.01 from the BiP-WT-vehicle group; two-way ANOVA with Tukey’s multiple comparisons test (A, n= 18-20
mice per group; B, n= 20-27 mice per group).
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that favoring CB1R-BiP association would reduce anxiety, a
frequent negative effect of CB1R overactivation. As CB1R-BiP
complexes also reside on GABAergic neurons in other brain
regions as the cortex and striatum, the possibility that BiP
binding controls additional CB1R-related behaviors remains
to be determined.
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